AIM ImmunoTech Inc. (AIM)
Company Description
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States.
The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS).
It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions.
In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease.
AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; Pharmaceutics International Inc.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente.
The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019.
AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.
| Country | United States |
| Founded | 1966 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 22 |
| CEO | Thomas K. Equels Esq., J.D., M.S. |
Contact Details
Address: 1212 N Hercules Ave Clearwater, Florida 33765 United States | |
| Phone | 727-461-3000 |
| Website | aimimmuno.com |
Stock Details
| Ticker Symbol | AIM |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000109471 |
| CUSIP Number | 00901B105 |
| ISIN Number | US00901B1052 |
| Employer ID | 74-1668471 |
| SIC Code | 3812 |
Key Executives
| Name | Position |
|---|---|
| Thomas K. Equels Esq., J.D., M.S. | Executive Vice Chairman, Chief Executive Officer and Pres |
| Peter W. Rodino III, Esq., J.D. | Chief Operating Officer, Executive Director of Gov.al Relations, General Counsel and Secretary |
| Robert Dickey IV, M.B.A. | Chief Financial Officer |
| Dr. David R. Strayer M.D. | Chief Scientific Officer and Medical Director |
| Ann Marie E. Coverly | Director of Administrative and Human Resources and Deputy Investor Relations Coordinator |
| Dr. Carol A. Smith | Chief Manufacturing Officer and Deputy Chief Scientific Officer |
| Jodie Pelz | Controller |
| Dr. Ralph Christopher Cavalli Ph.D. | Vice President of QC and Manufacturing |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 8, 2013 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Jul 2, 2013 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jul 1, 2013 | 11-K | Annual report of employee stock purchase, savings and similar plans |
| Jun 21, 2013 | 15-12G | Securities registration termination |
| Jun 19, 2013 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Jun 19, 2013 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Jun 19, 2013 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Jun 19, 2013 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Jun 19, 2013 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Jun 13, 2013 | 10-Q | Quarterly Report |